MCAM and ovarian carcinoma: From preliminary mechanical studies, we suggest that METCAM/MUC18 may subdue in vivo tumorigenesis and malignant progression of ovarian carcinoma cells by reducing their ability in proliferation, aerobic glycolysis (metabolism) and angiogenesis perhaps via suppressing the PI3K-AKT signaling pathway.